Influenza virus vaccine - CSL/Aventis Pasteur
Latest Information Update: 25 Sep 2021
Price :
$50 *
At a glance
- Originator CSL
- Developer CSL; sanofi pasteur
- Class Influenza virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Influenza virus infections
Most Recent Events
- 25 Feb 2002 Discontinued - Phase-I for Influenza virus infections in Australia (unspecified route)
- 25 Feb 2002 Discontinued - Phase-I for Influenza virus infections in Europe (unspecified route)
- 25 Feb 2002 Discontinued - Phase-I for Influenza virus infections in North America (unspecified route)